APOB and Hypercholesterolemia: Among all individuals undergoing lipid-lowering therapy for hypercholesterolaemia (23.0% CI = [20.9–25.1%]), 55.9% had TC levels below 190 mg/dL; 60.4% had LDL-C levels below 116 mg/dL; 69.6% had apoB levels below 100 mg/dL; and 54.4% had non-HDL-C levels below 130 mg/dL (Table 2).